BRPI0607669A2 - agente para profilaxia e tratamento de pancreatite - Google Patents

agente para profilaxia e tratamento de pancreatite

Info

Publication number
BRPI0607669A2
BRPI0607669A2 BRPI0607669-6A BRPI0607669A BRPI0607669A2 BR PI0607669 A2 BRPI0607669 A2 BR PI0607669A2 BR PI0607669 A BRPI0607669 A BR PI0607669A BR PI0607669 A2 BRPI0607669 A2 BR PI0607669A2
Authority
BR
Brazil
Prior art keywords
pancreatitis
receptor
prophylaxis
ht2a
receptor antagonist
Prior art date
Application number
BRPI0607669-6A
Other languages
English (en)
Inventor
Isamu Yamaguchi
Kentaro Hamada
Yasunari Kashihara
Original Assignee
Umn Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umn Pharma Inc filed Critical Umn Pharma Inc
Publication of BRPI0607669A2 publication Critical patent/BRPI0607669A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/067—Pancreatitis or colitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

AGENTE PARA PROFILAXIA E TRATAMENTO DE PANCREATITE. A presente invenção refere-se a uma composição farmacêutica para profilaxia e tratamento de pancreatite incluindo um antagonista de receptor 5-HT2A como um componente efetivo, em que a atividade de ligação (pKi) do antagonista de receptor 5-HT2A a um receptor 5-HT2A é superior em pelo menos 1,0 às atividades de ligação a um receptor 5-HT2B e um receptor 5-HT2C. Preferivelmente a atividade de ligação (pKi) do antagonista de receptor 5-HT2A ao receptor 5-HT2A é de pelo menos 7,0, e mais preferivelmente em pelo menos 8,0. A presente invenção também provê um método de identificação de uma substância candidata a agente profilático e terapêutico para pancreatite, incluindo determinar se uma substância em teste tem uma atividade antagonista a receptor 5-HT2A.
BRPI0607669-6A 2005-04-27 2006-04-27 agente para profilaxia e tratamento de pancreatite BRPI0607669A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005130408 2005-04-27
PCT/JP2006/308880 WO2006118212A1 (ja) 2005-04-27 2006-04-27 膵炎の予防および治療剤

Publications (1)

Publication Number Publication Date
BRPI0607669A2 true BRPI0607669A2 (pt) 2009-09-22

Family

ID=37308010

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607669-6A BRPI0607669A2 (pt) 2005-04-27 2006-04-27 agente para profilaxia e tratamento de pancreatite

Country Status (11)

Country Link
US (1) US20090075974A1 (pt)
EP (1) EP1879027B1 (pt)
JP (1) JPWO2006118212A1 (pt)
KR (1) KR20080012896A (pt)
CN (1) CN101198869A (pt)
AU (1) AU2006241806B2 (pt)
BR (1) BRPI0607669A2 (pt)
CA (1) CA2607524A1 (pt)
RU (1) RU2423692C2 (pt)
WO (1) WO2006118212A1 (pt)
ZA (1) ZA200709561B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138357A1 (en) 2015-02-27 2016-09-01 Kindred Biosciences, Inc. Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
WO2017023047A1 (ko) * 2015-08-03 2017-02-09 성균관대학교산학협력단 아리피프라졸을 유효성분으로 함유하는 염증성 질환 또는 암 예방 또는 치료용 조성물
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
PL3810100T3 (pl) 2018-06-20 2025-05-12 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
US20250388529A1 (en) * 2022-06-26 2025-12-25 Alexander Shulgin Research Institute, Inc. N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8900812D0 (en) * 1989-01-14 1989-03-08 Univ Manchester Pharmaceutical method and compositions
ZA972152B (en) * 1996-03-18 1997-09-17 Sankyo Co Treatment and prophylaxis of pancreatitis.
JP3968388B2 (ja) 1996-03-18 2007-08-29 第一三共株式会社 膵炎治療剤
JPH10212232A (ja) 1996-11-28 1998-08-11 Sankyo Co Ltd ジアリールアルカン誘導体を有効成分とする膵炎治療剤又は予防剤
JP2000063270A (ja) 1998-08-20 2000-02-29 Mitsubishi Chemicals Corp 膵炎の予防・治療剤
DE60134899D1 (de) * 2000-08-14 2008-08-28 Teva Pharma Herstellung von Risperidon
JP4240973B2 (ja) * 2002-09-26 2009-03-18 ソニー株式会社 画像処理システム、画像処理装置および方法、記録媒体、並びにプログラム
JP2005130408A (ja) 2003-10-27 2005-05-19 Fujitsu Ltd リンク集約方法およびリンク集約スイッチ

Also Published As

Publication number Publication date
EP1879027B1 (en) 2013-06-12
US20090075974A1 (en) 2009-03-19
JPWO2006118212A1 (ja) 2008-12-18
RU2423692C2 (ru) 2011-07-10
CN101198869A (zh) 2008-06-11
ZA200709561B (en) 2009-08-26
RU2007143980A (ru) 2009-06-10
WO2006118212A1 (ja) 2006-11-09
AU2006241806B2 (en) 2012-08-16
EP1879027A4 (en) 2009-01-07
CA2607524A1 (en) 2006-11-09
AU2006241806A1 (en) 2006-11-09
EP1879027A1 (en) 2008-01-16
KR20080012896A (ko) 2008-02-12

Similar Documents

Publication Publication Date Title
Dunkman et al. The injury response of aged tendons in the absence of biglycan and decorin
Hill et al. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment
BRPI0518307A2 (pt) mÉtodo e composiÇço de matÉria para tratar um indivÍduo tendo um cÂncer, kit, composiÇço farmacÊutica, mÉtodo para impregnar ou carregar um dispositivo implantÁvel de liberaÇço de droga, dispositivo implantÁvel de liberaÇço de droga, mÉtodo para avaliar a resposta de um indivÍduo tendo cÂncer a um tratamento usando um agonista de tlr3 ou selecionar um indivÍduo tendo um cÂncer que responde a um tratamento usando um agonista de tlr3, complexo, mÉtodo para determinar se um composto de teste É étil para o tratamento de cÂncer, e, uso de um agonista de tlr3
SA522441639B1 (ar) Egfr مثبطات تفارغية وطرق استخدامها
UY25794A1 (es) Procedimiento para la preparacion de compuestos derivados de adeninas, que son agonistas del receptor de la adenosina a2a
BRPI0713349A2 (pt) Inibidores de proteína tirosina fosfatase humana e métodos de utilização
MY155036A (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
EA201100427A1 (ru) Гетероциклические ингибиторы киназы
MX358640B (es) Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
BRPI0708038B8 (pt) derivado de cumarina, composição farmacêutica e agente terapêutico para um distúrbio proliferativo celular
NO20010446L (no) Substituert anilidforbindelser og metoder
BRPI0818437B8 (pt) anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
EA201100426A1 (ru) Бициклические ингибиторы киназы
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
CO6602158A2 (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
TNSN07005A1 (fr) Analogues tetrapeptidiques
NO20083523L (no) Sammensetning for vaginal anvendelse
MX2007007588A (es) Analogos de tetrahidroquinolina como agonistas muscarinicos.
BRPI0507031A (pt) composições nematocidas e métodos de uso dessas
MX359668B (es) Derivados de retinal y metodos para su uso en el tratamiento de trastornos visuales.
BRPI0607669A2 (pt) agente para profilaxia e tratamento de pancreatite
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
BRPI0705971A2 (pt) composiÇço para um prÉ-tratamento de espuma para instrumentos mÉdicos
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ISAMU YAMAGUCHI (JP)

B25A Requested transfer of rights approved

Owner name: CYTOPATHFINDER, INC. (JP)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: EXIGENCIA ANULADA (REF. A RPI NO 2189 DE 18/12/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO. )

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015.